Search research articles
Contact Us
Filters
Showing results (11-20 of 393) with videos related to
Page
of 40
Sort By:
Clinical Pharmacology : Advances and Applications
|
December 23, 2017
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
Alexandra Pender, Robin L Jones
Journal of Surgical Oncology
|
December 2, 2017
Systemic therapy in retroperitoneal sarcoma management
Anastasia Constantinidou, Robin L Jones
Cancer
|
March 16, 2017
Q-TWiST: What really matters to the cancer patient?
Olga Husson, Robin L Jones
Cancer Biology & Medicine
|
October 24, 2023
Recent advances in the systemic treatment of gastrointestinal stromal tumors
Robin L Jones, Marin Golčić
Future Oncology (London, England)
|
July 27, 2017
Olaratumab for the treatment of soft-tissue sarcoma
Alexandra Pender, Robin L Jones
Future Oncology (London, England)
|
August 18, 2023
Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial
Marina Symcox, Robin L Jones
GMS Ophthalmology Cases
|
September 15, 2016
The management of ophthalmic involvement in blue rubber bleb nevus syndrome
Bradley Petek, Robin L Jones
JAMA Oncology
|
February 1, 2019
Treatment of Desmoid Tumors in 2019
Alessandro Gronchi, Robin L Jones
JAMA Oncology
|
June 8, 2018
The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk
Alessandro Gronchi, Robin L Jones
The Lancet. Oncology
|
October 3, 2006
Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
Robin L Jones, Ian E Smith
Page
of 40
Search research articles
Search
Showing results (11-20 of 393) with videos related to
Sort By:
Page
of 40
Clinical Pharmacology : Advances and Applications
|
December 23, 2017
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
Alexandra Pender, Robin L Jones
Journal of Surgical Oncology
|
December 2, 2017
Systemic therapy in retroperitoneal sarcoma management
Anastasia Constantinidou, Robin L Jones
Cancer
|
March 16, 2017
Q-TWiST: What really matters to the cancer patient?
Olga Husson, Robin L Jones
Cancer Biology & Medicine
|
October 24, 2023
Recent advances in the systemic treatment of gastrointestinal stromal tumors
Robin L Jones, Marin Golčić
Future Oncology (London, England)
|
July 27, 2017
Olaratumab for the treatment of soft-tissue sarcoma
Alexandra Pender, Robin L Jones
Future Oncology (London, England)
|
August 18, 2023
Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial
Marina Symcox, Robin L Jones
GMS Ophthalmology Cases
|
September 15, 2016
The management of ophthalmic involvement in blue rubber bleb nevus syndrome
Bradley Petek, Robin L Jones
JAMA Oncology
|
February 1, 2019
Treatment of Desmoid Tumors in 2019
Alessandro Gronchi, Robin L Jones
JAMA Oncology
|
June 8, 2018
The Value of Neoadjuvant Chemotherapy in Localized High-Risk Soft-Tissue Sarcoma of the Extremities and Trunk
Alessandro Gronchi, Robin L Jones
The Lancet. Oncology
|
October 3, 2006
Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response
Robin L Jones, Ian E Smith
Page
of 40